Comparing SJ04 and Ovidrel in healthy women, for fertility treatment use
Compares how the body handles SJ04 and Ovidrel in healthy women.
Key facts
- Who runs it
- Suzhou Centergene Pharmaceuticals Co.,Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A Comparing Study Between SJ04 and Ovidrel® in Healthy Subjects
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 48 people, planned
- Started
- 12 Aug 2024
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- T-R (Test-Reference drug)
- R-T (Reference-Test drug)
- Record updated
- 10 February 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy women in China. It compares how the body handles two injected drugs, SJ04 and Ovidrel®.
- Age
- 20 to 40 years
- Sex
- Women only
- Earlier treatment
- Cannot join after using any LH preparation, hMG or hCG preparation within 3 months before screening. No prescription medicines within 14 days or 5 half-lives before screening. No over-the-counter medicines within 7 days or 5 half-lives before screening.
- Biomarker or test result
- Hormone levels (FSH, LH, PRL, E2, P, T) must be normal or not clinically significant. LH must be <5 IU/L and FSH <4 IU/L at Day -1. Weight at least 45.0 kg (99 lb) and body mass index 19.0~26.0 kg/m2. Regular menstrual cycle of 25-34 days.
Main reasons for not taking part
- Pregnant, breastfeeding, a positive pregnancy test, or planning children during the trial and for 3 months after
- Past or current tumors or diseases of the hypothalamus, pituitary, ovaries, uterus or breast, polycystic ovary syndrome or OHSS
- Ectopic pregnancy within 3 months before screening
- Positive test for hepatitis B, hepatitis C, HIV or syphilis
- Drug abuse, more than 14 units of alcohol per week, or smoking at least 5 cigarettes per day
This trial only enrols healthy participants. The registry sentence this rests on: 1. Healthy female subjects aged 20 to 40 years old (including boundary values).
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Healthy female subjects aged 20 to 40 years old (including boundary values)
- Weight not less than 45.0 kg, body mass index within the range of 19.0~26.0 kg/m2 (including boundary values)
- Menstrual cycle regularity, or menstrual regularity before taking oral contraceptives (25-34 days, including boundary values)
- The levels of follicle stimulating hormone(FSH), luteinizing hormone(LH), prolactin (PRL), estradiol (E2), progesterone (P), and testosterone (T) detected within 2-3 days after the last menstrual period before the first administration are within normal ranges or considered abnormal by the researchers to have no clinical significance
- LH levels \&lt;5 IU/L, FSH levels \&lt;4 IU/L at Day -1
Who cannot take part
- Use of any LH preparation, human menopausal gonadotropin (hMG) or human chorionic gonadotropin (hCG) preparation within 3 months prior to screening
- Previously or currently suffering from the following diseases: hypothalamic or pituitary tumors, unexplained ovarian enlargement or cyst, Abnormal uterine bleeding of unknown etiology, malignant tumors of the ovaries, uterus, or breast, active thromboembolic diseases, uncontrollable thyroid or adrenal dysfunction, endocrine disorders such as hyperprolactinemia, polycystic ovary syndrome, ovarian hyperstimulation syndrome (OHSS), and ovarian dysfunction, other malignant tumors or diseases of the hypothalamus, pituitary gland, ovaries, and uterus (excluding uterine fibroids)
- Ectopic pregnancy within 3 months prior to screening
- Prescription medications taken within 14 days or 5 half-lives prior to screening or over-the-counter medications (including proprietary and herbal medications) taken within 7 days or 5 half-lives prior to screening
- Excessive consumption of tea, coffee or caffeinated beverages in the 3 months prior to screening
- Drinking an average of more than 14 standard units of alcohol per week in the three months prior to screening, or inability to abstain from alcohol during the test period, or a positive breathalyser test result on the day of admission
- Smoke at least 5 cigarettes per day in the 3 months prior to screening or not be able to stop using any tobacco-based products during the trial
- Participated in a clinical trial of another drug within 28 days prior to screening and used the test drug, or participated in a clinical trial of a medical device within 1 month prior to screening
- History of blood donation or bleeding \&gt;400 ml within 3 months prior to screening
- Allergy or suspected allergy to any component of the experimental drug, control drug, GnRH, GnRH analogs used in this study
- Presence of clinically significant acute or chronic infection at screening or enrolment。
- Presence of localised disease affecting the hypodermic site, or inability to tolerate hypodermic injections。
- Difficulty in blood collection or inability to tolerate venipuncture, or history of needle or blood sickness
- A history of chronic or serious illness or disease of the liver, kidneys, gastrointestinal tract, endocrine system, cardiovascular, neurological, metabolic, haematological, respiratory, or autoimmune systems or an existing disease of one of the above systems which, in the judgement of the investigator, makes him or her unsuitable for enrolment
- Positive tests for hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, and syphilis spirochete antibody
- History of mental illness, substance abuse, drug dependence, or positive substance abuse screen (morphine, THC, methamphetamine, MDMA, ketamine) on the day of admission
- Abnormalities in vital signs, physical examination, laboratory tests (routine blood, blood biochemistry, urinalysis, coagulation, thyroid function), 12-lead electrocardiogram, liquid-based thin-layer cytometry (TCT), and ultrasound are judged by the investigator to be clinically significant and to warrant participation in the trial
- During pregnancy or breastfeeding, or a positive pregnancy test result. The subject (or his/her partner) is planning to have children (including sperm and egg donation) throughout the trial period and for 3 months after the end of the trial. Unwilling to use one or more non-pharmacological contraceptive methods (e.g. total abstinence, condoms, ligation, etc.) during the trial period
- Subjects who withdrew from the trial for their own reasons and who, in the opinion of the investigator, were otherwise unsuitable to participate in the trial
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 20 and 40 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a single-centre, randomised, open-label, single-dose, two-cycle, double-crossover study to compare the pharmacokinetics of SJ04 and Ovidrel® in healthy female subjects. Received a single subcutaneous injection administration of SJ04 Injection or Ovidrel®, both administered at a dose of 250 μg, once per cycle, and cross-administered after a washout period.
The 2 groups in the trial
- T-R Group (Test-Reference drug)Treatment being tested
SJ04 is injected first and Ovidrel® is injected after 2-week period
Treatment: T-R (Test-Reference drug)
- R-T Group(Reference-Test drug)Treatment being tested
Ovidrel® is injected first and SJ04 is injected after 2-week period
Treatment: R-T (Reference-Test drug)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I Clinical Trial to Compare the Pharmacokinetics, Safety and Immunogenicity of SJ04 and Ovidrel® in Healthy Female Subjects in China
- Plain-language title
- Comparing SJ04 and Ovidrel in healthy women, for fertility treatment useGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06599528, who can take part
- Record updated
- 10 February 2025